Canaccord Genuity reaffirmed their buy rating on shares of Sinclair Pharma PLC (LON:SPH) in a research report sent to investors on Friday morning. The firm currently has a GBX 58 ($0.72) target price on the specialty pharmaceutical company’s stock.

A number of other analysts have also issued reports on SPH. Peel Hunt reissued a buy rating and issued a GBX 68 ($0.85) price target on shares of Sinclair Pharma PLC in a research note on Wednesday, September 21st. Stifel Nicolaus reissued a buy rating and issued a GBX 49 ($0.61) price target on shares of Sinclair Pharma PLC in a research note on Thursday, September 1st. N+1 Singer reaffirmed a buy rating on shares of Sinclair Pharma PLC in a research note on Wednesday, September 21st. Finally, Royal Bank Of Canada reaffirmed an outperform rating on shares of Sinclair Pharma PLC in a research note on Thursday, September 15th. Six equities research analysts have rated the stock with a buy rating, Sinclair Pharma PLC has an average rating of Buy and an average target price of GBX 57.20 ($0.71).

Analyst Recommendations for Sinclair Pharma PLC (LON:SPH)

Sinclair Pharma PLC (LON:SPH) traded up 1.579917% during mid-day trading on Friday, hitting GBX 29.712126. 207,680 shares of the company were exchanged. Sinclair Pharma PLC has a 12 month low of GBX 26.00 and a 12 month high of GBX 61.33. The stock’s market cap is GBX 147.66 million. The firm has a 50 day moving average price of GBX 28.58 and a 200 day moving average price of GBX 30.65.

In other news, insider Jeff Thompson purchased 150,000 shares of the stock in a transaction dated Tuesday, October 4th. The stock was acquired at an average cost of GBX 29 ($0.36) per share, for a total transaction of £43,500 ($54,347.83). Also, insider Alan Olby purchased 6,748 shares of the stock in a transaction dated Monday, November 14th. The stock was purchased at an average price of GBX 29 ($0.36) per share, with a total value of £1,956.92 ($2,444.93).

About Sinclair Pharma PLC

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Stock Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related stocks with our FREE daily email newsletter.